Diazoxide
SIGMA/D9035
Synonym: 7-
CAS Number: 364-98-7
Empirical Formula (Hill Notation): C8H7ClN2O2S
Molecular Weight: 230.67
EC Number: 206-668-1
MDL Number: MFCD00078578
Linear Formula: C8H7ClN2O2S
Product Type: Chemical
| form | powder |
| InChI | 1S/C8H7ClN2O2S/c1-5-10-7- |
| InChI key | GDLBFKVLRPITMI-UHFFFAOYSA |
| originator | Schering Plough |
| Quality Level | 100 ![]() |
| SMILES string | CC1=Nc2ccc(Cl)cc2S(=O)(=O |
| solubility | 0.1 M NaOH: soluble |
| H2O: insoluble | |
| methanol: soluble |
| Application: | Diazoxide has been used for diazoxide infusion. It has also been used to prevent depolarization for K+-induced exocytosis. |
| Biochem/physiol Actions: | Selective ATP-sensitive K+ channel activator in both vascular smooth muscle and pancreatic β-cells; antihypertensive. |
| Features and Benefits: | This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by Schering Plough . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| General description: | Diazoxide is a nondiuretic benzothiadiazine, which is used for the treatment of hypoglycemia, von Gierke′s disease, acute and malignant hypertension. It acts as a beta cell KATP channel opener. Diazoxide prevents the secretion of insulin. |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 - H315 - H319 - H335 |
| Precautionary statements | P301 + P312 + P330 - P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xn |
| Risk Statements | 22-36/37/38 |
| Safety Statements | 22-26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| UNSPSC | 12352119 |


